Chemical Component Summary

Name3-[(4-azanyl-3-methyl-phenyl)methyl]-7-(furan-2-yl)-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine
Identifiers3-[(4-azanyl-3-methyl-phenyl)methyl]-7-(furan-2-yl)-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine
FormulaC16 H15 N7 O
Molecular Weight321.337
TypeNON-POLYMER
Isomeric SMILESCc1cc(ccc1N)Cn2c3c(c(nc(n3)N)c4ccco4)nn2
InChIInChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
InChIKeyHQSBCDPYXDGTCL-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count39
Chiral Atom Count0
Bond Count42
Aromatic Bond Count21

Drug Info: DrugBank

DrugBank IDDB06625 
NameVipadenant
Groups investigational
SynonymsVipadenant
IndicationInvestigated for use/treatment in parkinson's disease.
Categories
  • Adenosine A2 Receptor Antagonists
  • Neurotransmitter Agents
  • Purinergic Agents
  • Purinergic Antagonists
  • Purinergic P1 Receptor Antagonists
CAS number442908-10-3

Related Resource References

Resource NameReference
Pharos CHEMBL447664
PubChem 21874557
ChEMBL CHEMBL447664